FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report - Top-Institutions - MDSpire

FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report

  • By

  • Mosè Parisi

  • Nicola Molitierno

  • Claudia Alberti

  • Delia Gagliardi

  • Daniele Velardo

  • Giacomo Pietro Comi

  • Stefania Paola Corti

  • June 19, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Myasthenia Gravis Foundation of America
    Myasthenia Gravis Foundation of America

    Washington, DC

    Key Differentiators

    • Neurology

  • #2

    our center
    our center

    Unknown, Unknown

    Key Differentiators

    • Neurology

  • #3

    another institution
    another institution

    Unknown, Unknown

    Key Differentiators

    • Neurology

  • #4

    Charité—University Hospital Berlin
    Charité—University Hospital Berlin

    Berlin, Germany

    Key Differentiators

    • Neurology

  • #5

    First Affiliated Hospital of Shandong First Medical University
    First Affiliated Hospital of Shandong First Medical University

    Jinan, Shandong

    Key Differentiators

    • Neurology

Original Source(s)

FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report

  • by Mosè Parisi, Nicola Molitierno, Claudia Alberti, Delia Gagliardi, Daniele Velardo, Giacomo Pietro Comi, Stefania Paola Corti

  • June 19, 2026

Related Content

Long-term survival with stereotactic radiosurgery and 100+ cycles of Keytruda in a patient with brain metastases from melanoma

Enhancing motor function after stroke: a systematic review and meta-analysis of bioelectrical feedback interventions

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.